Treats chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B…. ANDA 203260, held by Hetero Labs Ltd V. Lamivudine.
As of Nov 16, 2026, ANDA 203260 (Lamivudine), held by Hetero Labs Ltd V, was first approved by FDA on Jan 2, 2014, with 3 approved supplements and 0 published complete response letters.
Lamivudine tablets (HBV) are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation. The following points should be considered when initiating therapy with lamivudine tablets (HBV):
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 2, 2014 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lamivudine100MG · tablet;oral | Lamivudine | Rx |
| May 8, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 8, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| May 8, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 2, 2014 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters